Novartis | NVS
Stock Price
103.80
Daily Change
0.24 0.23%
Monthly
-10.30%
Yearly
6.20%
Q4 Forecast
108.10


Peers Price Chg Day Year Date
AbbVie 181.30 3.81 2.15% 30.35% Nov/26
Amgen 280.01 -14.08 -4.79% 5.95% Nov/26
AstraZeneca 10,490.00 -2.00 -0.02% 5.96% Nov/27
Biogen 157.76 -0.92 -0.58% -31.05% Nov/26
Bristol-Myers Squibb 58.64 -0.06 -0.10% 19.62% Nov/26
Corcept Therapeutics 58.58 -0.45 -0.76% 131.82% Nov/26
Catalent 60.76 -0.36 -0.58% 55.36% Nov/26
Gilead Sciences 91.33 0.90 1.00% 21.90% Nov/26
GlaxoSmithKline 1,341.00 3.00 0.22% -5.01% Nov/27
Glaxosmithkline 34.02 -0.13 -0.38% -4.52% Nov/26
J&J 154.37 -1.38 -0.89% 2.04% Nov/26
Eli Lilly 789.09 36.87 4.90% 33.40% Nov/26
Merck 101.60 0.11 0.11% 0.17% Nov/26
Novartis 103.80 0.24 0.23% 6.20% Nov/26
Prestige Brands 83.18 -1.47 -1.74% 43.29% Nov/26
Pacira 16.78 -0.64 -3.67% -36.25% Nov/26
Pfizer 25.76 -0.41 -1.57% -14.53% Nov/26
Perrigo 28.32 -0.07 -0.25% -7.90% Nov/26
Drreddys Laboratories 14.14 -0.18 -1.26% -79.11% Nov/26
Roche Holding 252.25 0.85 0.34% 6.93% Nov/27
Sanofi 91.91 0.19 0.21% 7.17% Nov/27
Sanofi 48.27 -0.09 -0.18% 1.30% Nov/26
Supernus Pharmaceuticals 36.14 0.04 0.11% 33.41% Nov/26
Bausch Health Companies 11.10 -0.03 -0.27% 18.34% Nov/26
Canopy Growth 5.55 -0.26 -4.48% -25.00% Nov/26
Zoetis 175.60 -2.98 -1.67% -1.78% Nov/26

Indexes Price Day Year Date
EU600 504 -1.44 -0.28% 10.38% Nov/27

Novartis traded at $103.80 this Tuesday November 26th, increasing $0.24 or 0.23 percent since the previous trading session. Looking back, over the last four weeks, Novartis gained 10.30 percent. Over the last 12 months, its price rose by 6.20 percent. Looking ahead, we forecast Novartis to be priced at 108.10 by the end of this quarter and at 104.48 in one year, according to Trading Economics global macro models projections and analysts expectations.

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.